ClinicalTrials.govcontrolled
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
ClinicalTrials.gov study NCT06500702. IPD Sharing: YES. Countries: 22. Publications: 1.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8
Topics
Dataset details
- Repository
- ClinicalTrials.gov
- Published
- February 11, 2026
- License
- IPD-YES
- DOI
- clinicaltrials.gov/NCT06500702
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.